
Oryzon to invest eur 20 million to develop new drugs
Catalan Economy
10 Sep 2009
Biotech company oryzon genomics has announced a four-year program to invest eur 20 million in the development of new drugs. oryzon ceo carlos buesa indicated that the company would use the resources to strengthen its research on biomarkers and antibody therapy.
oryzon recently opened its new 2,300-square-meter corporate headquarters in cornellà de llobregat (barcelona), with an investment of eur 2.5 million. the company expects revenue of eur 8 million for its current fiscal year.
source: expansión catalunya, 08/09/09
Related News and Success stories.
-
10 Mar 2025
Catalonia Trade & Investment breaks records with over €1B in foreign investment attracted in 2024
-
07 Mar 2025
MWC25 draws 109,000 attendees in Barcelona for a week of AI and innovation
-
25 Feb 2025
2024 Breaks Records for Catalan Startups with 2,285 Companies
-
18 Feb 2025
Catalonia’s health startups and scaleups set investment record, rising 55% from last year